Rini, Brian I <br/><br/>
Clinical response to therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: impact of patient characteristics and Von Hippel-Lindau gene status.  [electronic resource] 

 -  BJU international  Oct 2006 
 - 756-62 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1464-4096 
<br/><br/><label>Standard No.: </label>10.1111/j.1464-410X.2006.06376.x  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Angiogenesis Inhibitors--therapeutic use<br/>Antibodies, Monoclonal--administration & dosage<br/>Antibodies, Monoclonal, Humanized<br/>Antineoplastic Combined Chemotherapy Protocols--therapeutic use<br/>Axitinib<br/>Bevacizumab<br/>Carcinoma, Renal Cell--complications<br/>Female<br/>Humans<br/>Imidazoles--administration & dosage<br/>Indazoles--administration & dosage<br/>Indoles--administration & dosage<br/>Kidney Neoplasms--complications<br/>Male<br/>Middle Aged<br/>Mutation--genetics<br/>Pyrroles--administration & dosage<br/>Sunitinib<br/>Treatment Outcome<br/>Vascular Endothelial Growth Factor A--drug effects<br/>von Hippel-Lindau Disease--complications